Media headlines about Cancer Genetics (NASDAQ:CGIX) have been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.0391653568141 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Cancer Genetics (NASDAQ:CGIX) traded up $0.10 during trading hours on Tuesday, hitting $1.83. 75,500 shares of the stock traded hands, compared to its average volume of 157,458. The firm has a market cap of $50.56, a PE ratio of -2.23 and a beta of 1.14. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a one year low of $1.55 and a one year high of $5.30.

Several analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the company a “buy” rating in a research report on Tuesday, February 6th. ValuEngine upgraded shares of Cancer Genetics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Maxim Group set a $6.00 target price on shares of Cancer Genetics and gave the company a “buy” rating in a research report on Wednesday, December 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Cancer Genetics has a consensus rating of “Hold” and a consensus price target of $5.56.

In other news, Director John Pappajohn bought 150,000 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $1.86 per share, for a total transaction of $279,000.00. Following the transaction, the director now owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 21.30% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cancer Genetics (CGIX) Stock Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.